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Abstract
Background: Diagnosis of ovarian carcinoma is in urgent need for new complementary biomarkers for early stage
detection. Proteins that are aberrantly excreted in the urine of cancer patients are excellent biomarker candidates
for development of new noninvasive protocol for early diagnosis and screening purposes. In the present study,
urine samples from patients with ovarian carcinoma were analysed by two-dimensional gel electrophoresis and the
profiles generated were compared to those similarly obtained from age-matched cancer negative women.
Results: Significant reduced levels of CD59, kininogen-1 and a 39 kDa fragment of inter-alpha-trypsin inhibitor
heavy chain H4 (ITIH4), and enhanced excretion of a 19 kDa fragment of albumin, were detected in the urine of
patients with ovarian carcinoma compared to the control subjects. The different altered levels of the proteins were
confirmed by Western blotting using antisera and a lectin that bind to the respective proteins.
Conclusion: CD59, kininogen-1 and fragments of ITIH4 and albumin may be used as complementary biomarkers in
the development of new noninvasive protocols for diagnosis and screening of ovarian carcinoma.
Background
Ovarian carcinoma is the leading cause of death among
gynaecologic malignancy. It is the fourth most common
cancer affecting women in Malaysia [1]. Patients with
ovarian carcinoma often presented themselves at an
advance stage of cancer mainly because of the lack of
biomarker for early diagnosis and that the cancer is
usually asymptomatic at the early stages [2]. Once the
cancer is detected at the advance stage, the five-year
survival rate of the patients decreases to 25% even when
appropriate treatments were provided [3,4].
The gel-based proteomic analysis provides a conveni-
ent method to compare the levels of proteins in bodily
fluid samples. In the search for new protein biomarker
candidates with clinical diagnostic value, substantial
progress has been made in the proteomic analysis of
serum samples of patients with different cancers [5-7].
In contrast, fewer studies have been carried out on the
urine samples of cancer patients. This is despite that
urine is generally a better sample for investigative and
screening purposes and that the use of urine protein
biomarkers such as albumin and human chorionic gona-
dotropin for clinical diagnosis has been a long standing
practice.
The proteomic analysis of urine offers ample opportu-
nities for clinical translation [8,9]. To date, proteomic
experiments that have been conducted on urine were
not confined to patients suffering from diseases of the
genitourinary system [10] but were also carried out on
those with atherosclerosis [11], sleep disorder [12] and
cancers of the bladder [13], pancreas [14,15], lung [16]
and colon [17]. Proteomic investigation has been per-
formed on urine of patients with ovarian carcinoma but
is currently restricted to the low molecular weight pep-
tide analysis using the SELDI-TOF-MS approach [18].
In the present study, urine protein samples from patients
with ovarian carcinoma and cancer negative women
were subjected to the conventional two-dimensional
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that were aberrantly excreted by the cancer patients, rela-
tive to control subjects, were identified by mass spectrome-
try and their altered levels in the patients urine were
confirmed by Western blotting using antisera and a lectin
that bind to the respective proteins.
Results
2-DE profiles of urine proteins
Separation of urine protein samples by 2-DE resulted in
highly resolved profiles comprising more than ten clusters
of protein spots. Panel A of Figure 1 demonstrates a repre-
sentative urinary proteome profile obtained from a control
subject. Seven protein spot clusters consistently appeared
in all the 15 control samples analyzed and there was no
apparent difference in the intensity of the spots between
the individual urine samples studied. When the gel-based
proteomic analysis was performed on urine protein sam-
ples from patients with ovarian carcinoma (n = 11), differ-
ent 2-DE profiles were obtained (Figure 1, panel B). Three
protein spot clusters which consistently appeared in the
control profile were either not detected or were reduced
in intensity in the cancer patients while one protein spot
appeared enhanced in a considerable number of the
patients’ 2-DE gels. The levels of the other protein spot
clusters were comparable to those detected in the urinary
proteome profiles of the control subjects.
Identification of aberrantly excreted urine proteins
Subjecting the spot clusters of urine proteins that were
aberrantly excreted to mass spectrometry and database
search identified them as CD59, kininogen-1, inter-
alpha-trypsin inhibitor heavy chain H4 (ITIH4) and
albumin. Table 1 shows a summary of the data acquired.
High probability-based MOWSE scores were obtained
for all the urine proteins. Among the four urine proteins
of interest, ITIH4 and albumin demonstrated large dis-
crepancies between the experimental masses that were
estimated based on their mobilities in the 2-DE gels and
their theoretically calculated mass. This suggested that
the ITIH4 and albumin spots detected in the 2-DE urin-
ary profiles were truncated fragments of their native
molecules.
In the case of ITIH4 (Q14624), the peptide sequences
identified with high confidence from the MS/MS corre-
lated to the C-terminal region of the protein, when they
were checked against the Swiss-Prot database (Table 2).
Sequences obtained were those that spanned within the
kallikrein-generated 35 kDa fragment region of ITIH4
(amino acids 696-930). However, molecular mass esti-
mation based on its relative mobility in 2-DE gels indi-
cated a larger fragment of approximately 39 kDa. In
case of albumin (P02768), the sequences derived from
Figure 1 Typical 2-DE urine protein profiles of controls and
patients with ovarian cancer. Panels A and B demonstrate the
representative 2-DE urine protein profiles of control subjects and
ovarian cancer patients, respectively. The aberrantly excreted urine
protein spot clusters were marked in circles. KNG1, ITIH4f and ALBUf
refer to kininogen-1 and fragments of inter-alpha-trypsin inhibitor
heavy chain H4 and albumin, respectively. Acid side of 2-DE gel is
to the left and relative molecular mass declines from the top.
Table 1 Mass spectrometric identification of spot clusters
















CD59 P13987 14.168/6.02 19.43 160 18




ALBU P02768 69.321/5.92 19.45 161 8
Spot ID are as in Fig. 1. KNG1, ITIH4 and ALBU refer to kininogen-1, inter-
alpha-trypsin inhibitor heavy chain H4 and albumin, respectively.
# Accession numbers are from the Mascot database http://www.matrixscience.
com.
*Estimation based on migration in the 2-DE gels relative to protein markers.
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to 281 of the molecule (Table 2).
Image analysis of 2-DE gels
The different altered levels of CD59, kininogen-1 and
fragments of ITIH4 and albumin in the urine of patients
with ovarian carcinoma, relative to the controls, was
confirmed when their 2-DE urine protein profiles were
subjected to image analysis using the Image Master 2 D
Platinum Software 7.0. Image analysis also confirmed
that the levels of the other highly resolved urine protein
spot clusters were comparable between cancer patients
and controls. Figure 2 demonstrates the mean percen-
tage of volume contribution of the four urine proteins
of interest in control subjects and patients with ovarian
carcinoma. When taken as overall, the levels of CD59,
kininogen-1 and ITIH4 fragment were significantly
lower in ovarian carcinoma patients by 3.6-, 2.5- and
1.9-folds, respectively, compared to those excreted by
the control subjects. In contrast, the 19 kDa fragment of
albumin appeared 274-fold higher in the patients urine
(Table 3).
SDS-polyacrylamide gel electrophoresis and Western
blotting
Further confirmation of the altered levels of CD59, kini-
nogen-1 and fragments of ITIH4 and albumin in the
urine of patients with ovarian carcinoma relative to
those of the control subjects was performed using anti-
bodies and a lectin that bind to the respective proteins
that were blotted onto membranes. Figure 3 demon-
strates the respective interactions of specific antibodies
and the CGB lectin with the four proteins of interest in
pooled urine samples of patients and control subjects.
In case of the 19 kDa albumin fragment, interaction
appeared to be detected only in the pooled urine of
patients with ovarian carcinoma compared to that of the
controls, while the inverse was observed for CD59,
kininogen-1 and the 39 kDa fragment of ITIH4.
Discussion
In the present proteomic profiling study, the significant
reduced excretion of CD59, kininogen-1 and a 39 kDa
fragment of ITIH4, and the enhanced levels of a 19 kDa
fragment of albumin were detected in the urine samples
of patients with ovarian carcinoma relative to those of
the control subjects. Their different altered levels in the
urine of ovarian cancer patients were confirmed by
Western blotting using antisera and a lectin that bind to
the respective proteins. These urinary proteins have
potential to be used as complementary molecular indica-
tors for noninvasive diagnoses and/or monitoring of
ovarian carcinoma, although this requires further confir-
mation involving a larger scale clinical investigation.
CD59, a cell surface molecule, functions to inhibit the
membrane attack complex of the complement pathway.
The soluble form of CD59 is usually found in normal
human urine at a concentration of about 3.7 μg/ml.
However, it is barely detectable in the blood (between
33-119 ng/ml), and even that only in the presence of
detergents [19,20]. To the best of our knowledge, the
present study is the first to report the decreased levels
of CD59 in the urine of patients with ovarian cancer
although similar reduced excretion of the protein had
previously been reported in the urine of patients with
bladder cancer [13] and pancreatic ductal adenocarci-
noma [14]. The reason for the low levels of CD59 in the
urine of cancer patients is not understood. One possibi-
lity is that since the turnover of cancer cells bearing
CD59 is low as they are generally “immortal”,l e s so ft h e
cell surface molecules are being solubilized and excreted
i nt h eu r i n e .H o w e v e r ,t h i sr e m a i n st ob ef u r t h e r
proven.
Like CD59, kininogen-1 is also detectable in the urine
of healthy individuals. Previous studies performed on
serum and plasma samples have shown that the expres-
sion of kininogen-1 was significantly reduced in patients
with gastrointestinal cancer [21], breast cancer [22] and
two different types of cervical cancer [23]. Since kinino-
gen-1 is known for its antiangiogenic properties and
inhibitory action on the proliferation of endothelial cells
[24], its lowered expression in serum/plasma of the can-
cer patients was believed to have contributed to the sur-
vival of the cancer cells [23]. In view of these previous
reports, it was not surprising to find similar reduced
levels of kininogen-1 in the urine of patients with ovar-
ian carcinoma in this study. However, the aberrant kini-
nogen-1 expression is apparently not cancer-specific
since decreased levels of the protein had previously been
reported in the urine of patients with chronic pancreati-
tis [14], interstitial cystitis [25] and IgA nephropathy
Table 2 List of matched peptide sequences of high
confidence identified from MS/MS analysis
Peptide sequence Ion score Amino acid
39 kDa ITIH4 spots
R.QGPVNLLSDPEQGVEVTGQYER.E 19 754 - 775
K.WKETLFSVMPGLK.M 31 814 - 826
R.RLDYQEGPPGVEISCWSVEL.- 24 911 - 930
19 kDa albumin spots
K.QEPERNECFLQHK.D 30 118 - 130
K.DDNPNLPR.L 37 131 - 138
K.YLYEIAR.R 43 162 - 168
K.LDELRDEGK.A 10 206 - 214
K.VHTECCHGDLLECADDR.A 41 265 - 281
Sequences of peptide were checked against ITIH4 (Q14624; 930 amino acids)
and albumin (P02768; 585 amino acids) in the Swiss-Prot database.
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gen-1 in these diseases may have been different.
The precise reason for the reduced levels of the ITIH4
fragment in the urine of patients with ovarian carcinoma
that is observed in this study is currently not understood.
The estimated molecular mass of the urine ITIH4 frag-
ment indicated that it was slightly larger than its reported
35 kDa serum counterpart in the ovarian carcinoma
patients [27]. Detection of the different sizes of ITIH4
fragments was not surprising as previous studies using
SELDI-TOF-MS have demonstrated that ITIH4 was
extensively processed within its proline-rich region in the
human serum. In different diseases including ovarian
carcinoma, different fragments were shown to be proteoly-
tically generated [28]. While the present study demon-
strated the reduced levels of the 39 kDa ITIH4 fragment
in the urine of patients with ovarian carcinoma, our pre-
vious data showed the up-regulated levels of a 35 kDa
ITIH4 fragment in the serum samples of the patients [27].
This inverse relationship and the difference in the molecu-
lar masses of the ITIH4 fragments detected in the respec-
tive samples suggest presence of a selective glomerular
filtration mechanism that retained the 35 kDa fragment in
the blood but allowed its 39 kDa counterpart to be
excreted in the urine.
Based on their resolved locations in the 2-DE gels and
MS/MS derived sequences, the enhanced albumin spots
detected in the urine of ovarian cancer patients in this
Figure 2 Relative excretion of urine proteins by control subjects and patients with ovarian cancer. The percentage of volume
contribution was determined using the Image Master 2D Platinum Software 7.0. Image analysis performed on protein spot clusters that
appeared consistently within each cohort of urine samples demonstrated the aberrant excretion of CD59, kininogen-1 (KNG1), ITIH4 (39 kDa
fragment) and 19 kDa fragment of albumin (ALBUf) by patients with ovarian carcinoma (OCa).
Table 3 Relative excretion of urine proteins in ovarian
cancer
Urine proteins Fold changes* p
CD59 - 3.60 0.001
Kininogen-1 - 2.50 0.001
ITIH4
tf - 1.86 0.002
Albumin
tf + 274.07 0.018
*Fold expression changes are relative to the control values
(-) decrease in expression; (+) increase in expression
tf Truncated fragment of protein
A p value of less than 0.05 is considered significant.
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of amino acids between positions 118 to 281, and with
an approximate molecular mass of 19 kDa. The human
urine is known to contain low levels of albumin frag-
ments, with some polypeptides containing discontinuous
sequences joined by unknown crosslinks [29]. Since the
19 kDa albumin fragment was present only in trace
quantities in the urine of the control subjects, it may be
used as a complementary urine biomarker to differenti-
ate ovarian carcinoma patients from healthy individuals.
Conclusion
The proteomic profiling of urine samples demonstrated
reduced levels of CD59, kininogen-1 and a 39 kDa
ITIH4 fragment, as well as the enhanced excretion of a
19 kDa fragment of albumin in patients with ovarian
carcinoma compared to control women. This observa-
tion may be applied in the development of noninvasive
protocols for diagnosis and/or monitoring of the cancer.
Methods
Urine samples and processing
Urine samples were collected from patients newly con-
firmed with stages II and III ovarian carcinoma (n =
11), prior to treatment, at the University of Malaya
Medical Centre (UMMC), Kuala Lumpur. All patients
showed normal serum creatinine values. Control urine
samples were collected randomly from age-matched
cancer negative women (n = 15). Samples obtained were
with consent and approval granted by the ethical com-
mittee of UMMC in accordance to the ICH GCP guide-
line and the Declaration of Helsinki. The subjects
were of different ethnic background (Malay, Chinese
and Indian). Sodium azide was immediately added
to the urine upon collection to a final concentration of
20 mM. The samples were centrifuged at 10,000 rpm at
4°C and the supernatant was collected and dialyzed
against distilled water. The urine proteins were ali-
quoted, freeze-dried and kept at -20°C. Protein content
was determined using the Pierce BCA protein assay kit
(Thermo Fisher Scientific, Rockford USA).
Two-dimensional gel electrophoresis
IPG strips (pH 3-10, 11 cm) were rehydrated overnight
in presence of 300 μg urine proteins in 200 μl rehydra-
tion solution (8 M urea, 0.5% v/v Pharmalyte 3-10, 0.5%
v/v NP-40). Isoelectric focusing was performed using
the Multiphor™ II Electrophoresis unit (GE Healthcare,
Uppsala, Sweden) for a total of 12001 Vh at 20°C. The
samples were then reduced by incubation of the strips
in equilibrium buffer (50 mM Tris-HCl pH 8.8, 6 M
urea, 30% glycerol, 2% SDS) containing 1% w/v DTT
f o r1 5m i np r i o rt oS D S - P A G E, and alkylated using
2.5% w/v iodoacetamide in the same equilibrium buffer
Figure 3 Interaction of antisera and CGB lectin with aberrantly excreted urine proteins. Pooled urine samples of ovarian cancer patients
(OCa) and those of control subjects (Con) were subjected to SDS-PAGE and Western blotting before being independently exposed to antisera
that bind to CD59, kininogen-1 and albumin as well as the ITIH4 binding CGB lectin.
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12.5% polyacrylamide gels and electrophoresis was per-
formed at 25 mA per gel.
Silver staining and image analysis
The 2-DE gels were developed by silver staining accord-
ing to the method of Heukeshoven and Dernick [30]
and scanned using the Image Scanner III. For mass
spectrometric analysis, staining of gels was performed in
absence of glutaraldehyde. Protein profiles were evalu-
ated using the ImageMaster™ 2 D Platinum Software
(Version 7). Image analysis was restricted to protein
spot clusters that appeared consistently within each
cohort of urine samples. The levels of proteins in each
urine sample were evaluated as a percentage of volume
contribution (%vol) to eliminate possible variations due
to differential staining.
Mass spectrometry and database search
Protein spots of interest were excised from the silver
stained gels and subjected to in-gel digestion according
to the method of Shevchenko et al. [31]. Gel plugs were
destained using 50 mM sodium thiosulphate: 15 mM
potassium ferricyanide (1:1; v/v). Proteins in the plugs
were reduced with 10 mM DTT in 100 mM ammonium
bicarbonate for 30 min at 60°C, followed by alkylation
with 55 mM iodoacetamide in the same solution for 20
min at RT in dark. The gel plugs were washed with 50%
acetonitrile (ACN) in 100 mM ammonium bicarbonate,
dehydrated by incubating in 50 μlA C Nf o r1 5m i na n d
left to dry using a speed vac. Proteins were then
digested with 7 ng/μl trypsin in 50 mM ammonium
bicarbonate overnight at 37°C, extracted twice using
50% ACN and concentrated using the speed vac. The
resulting peptide solutions were desalted and concen-
trated using zip-tips (Perfect Pure C18, Eppendorf,
Hamburg, Germany). One μl aliquot was spotted onto a
sample plate with 1 μlo fm a t r i xs o l u t i o n( a-cyano-
4hydroxycinnamic acid, 10 mg/ml in 70% v/v ACN,
0.1% v/v TFA) and was allowed to air dry.
MALDI mass spectrometry was performed using the
Applied Biosystems 4800 Proteomics Analyser. Spectra
were initially acquired in reflecton mode in the mass
range of 1000 to 4000 Da. The instrument was then
switched to MS/MS (TOF/TOF). Ten strongest peptides
from the MS scan were isolated, fragmented and reac-
celerated to measure their masses and intensities. The
data were exported in a format suitable for submission
to the MASCOT database search program (Matrix
Science Ltd., London, UK) and searched against ‘all
entries’. Identification was accepted when ≥ 5 peptide
masses matched to a particular protein (mass error ± 50
ppm - 1 missed cleavage) and the MOWSE score was
over the threshold score at p = 0.05.
SDS-polyacrylamide gel electrophoresis and Western
blotting
Urine samples of patients with ovarian carcinoma (n =
11) and control subjects (n = 15) were separately pooled
and subjected to unidimensional SDS-PAGE according
to the method of Laemmli [32]. Gels consisting of 12.5%
w/v acylamide were used. Separated proteins were trans-
ferred to nitrocellulose membranes (0.45 μm) using the
NovaBlot Kit of Multiphor II Electrophoresis System
(GE Healthcare, Uppsala, Sweden) at 0.8 mA/cm
2.
The membranes were blocked with 3% w/v gelatine in
Tris-buffered saline (TBS), pH 7.5, for 1 h at RT and
washed three times with thes a m eb u f f e r .T h e yw e r e
then incubated for another 1 h in the following HRP-
conjugate solutions: (1) anti-human CD59 (Abcam,
Cambridge, UK - Cat. No. ab9182, at 1:5 dilution), (2)
anti-human kininogen-1 (Abnova, Jhongli, Taiwan - Cat.
No. H00003827-B01, at 1:500 dilution), (3) anti-albumin
(Sigma Chemical Company, St. Louis, MO USA - Cat.
No. A0433, at 1:40 dilution) and (4) champedak galac-
tose binding (CGB) lectin (0.01 μg/ml) diluted/dissolved
in TBST. The use of the CGB lectin to detect the
C-terminal O-glycosylated ITIH4 fragment has been
previously reported [27]. Development of the Western
blot was performed using 25 ng 3,3’-diaminobenzidine
and 5 μl3 0 %v / vH 2O2 in 50 ml TBS. The reaction was
stopped by washing the membranes with distilled water.
Statistical analysis
All values are presented as mean ± SD. The Student’s
t-test was used to analyze significance of differences
between control subjects and patients. A p value of less
than 0.05 was considered significant.
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